(Q61627994)

English

A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma

scientific article published on 01 September 2012

In more languages
default for all languages
No label defined

No description defined

Statements

A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit